Essex Bio-Technology (01061) said it entered into a research collaboration agreement with AC Immune SA (ACI) to undertake the pre-clinical and clinical co-development of a novel biological therapeutic for the treatment of neurodegenerative diseases (such as Alzheimer's disease and frontotemporal dementia) and neuroinflammation.
ACI is a clinical stage Swiss-based biopharmaceutical company listed on the NASDAQ Stock Market of the United States (NASDAQ: ACIU) focusing on neurodegenerative diseases.
etnet榮獲HKEX Awards 2023 「最佳表現證券數據供應商」大獎► 了解詳情